Remarkable antibiofilm activity of ciprofloxacin, cefoxitin, and tobramycin, by themselves or in combination, against enteroaggregative Escherichia coli in vitro
- PMID: 37657231
- DOI: 10.1016/j.diagmicrobio.2023.116048
Remarkable antibiofilm activity of ciprofloxacin, cefoxitin, and tobramycin, by themselves or in combination, against enteroaggregative Escherichia coli in vitro
Abstract
Enteroaggregative Escherichia coli (EAEC), a biofilm forming pathogen, causes acute and persistent diarrhea worldwide, requiring antimicrobial therapy in severe or persistent cases. To determine the susceptibility of EAEC biofilm to antimicrobials, as single-agent or combined therapy, biofilm formation was investigated using EAEC clinical strains via peg lid. Of the 78 initially analyzed strains, 35 could form biofilms, 15 (42.9%; 15/35) were resistant to at least 1 tested antimicrobial and 20 (57.1%) were susceptible to all of them in the planktonic form. The biofilms of these susceptible strains were challenged against chosen antimicrobials, and displayed resistance to tetracycline, trimethoprim-sulfamethoxazole, chloramphenicol, ampicillin, cefotaxime, ceftriaxone (85%-100%), tobramycin (25%), cefoxitin (20%), and ciprofloxacin (5%). Moreover, ciprofloxacin combined with ampicillin, and tobramycin eradicated the biofilm of 2 of the 4 tested strains. Ciprofloxacin, cefoxitin, and tobramycin maintained their activity well against EAEC biofilm, suggesting their possible effectiveness to treat diarrhea caused by biofilm-forming EAEC strains.
Keywords: Antimicrobial agents; Biofilm; Enteroaggregative Escherichia coli.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
CHARACTERIZATION OF ENTEROAGGREGATIVE ESCHERICHIA COLI AMONG DIARRHEAL CHILDRENIN WESTERN BRAZILIAN AMAZON.Arq Gastroenterol. 2018 Oct-Dec;55(4):390-396. doi: 10.1590/S0004-2803.201800000-84. Arq Gastroenterol. 2018. PMID: 30785524
-
Emergence of Resistance to Quinolones and β-Lactam Antibiotics in Enteroaggregative and Enterotoxigenic Escherichia coli Causing Traveler's Diarrhea.Antimicrob Agents Chemother. 2019 Jan 29;63(2):e01745-18. doi: 10.1128/AAC.01745-18. Print 2019 Feb. Antimicrob Agents Chemother. 2019. PMID: 30478165 Free PMC article.
-
Antibiofilm agents with therapeutic potential against enteroaggregative Escherichia coli.PLoS Negl Trop Dis. 2022 Oct 6;16(10):e0010809. doi: 10.1371/journal.pntd.0010809. eCollection 2022 Oct. PLoS Negl Trop Dis. 2022. PMID: 36201560 Free PMC article.
-
A review of an emerging enteric pathogen: enteroaggregative Escherichia coli.J Med Microbiol. 2006 Oct;55(Pt 10):1303-1311. doi: 10.1099/jmm.0.46674-0. J Med Microbiol. 2006. PMID: 17005776 Review.
-
Enteroaggregative Escherichia coli: an emerging enteric pathogen.Am J Gastroenterol. 2004 Feb;99(2):383-9. doi: 10.1111/j.1572-0241.2004.04041.x. Am J Gastroenterol. 2004. PMID: 15046233 Review.
Cited by
-
Fluoroquinolones and Biofilm: A Narrative Review.Pharmaceuticals (Basel). 2024 Dec 11;17(12):1673. doi: 10.3390/ph17121673. Pharmaceuticals (Basel). 2024. PMID: 39770514 Free PMC article. Review.
-
Novel BRICHOS-Related Antimicrobial Peptides from the Marine Worm Heteromastus filiformis: Transcriptome Mining, Synthesis, Biological Activities, and Therapeutic Potential.Mar Drugs. 2023 Dec 14;21(12):639. doi: 10.3390/md21120639. Mar Drugs. 2023. PMID: 38132960 Free PMC article.
-
Antimicrobial proteins from oyster hemolymph improve the efficacy of conventional antibiotics.PLoS One. 2025 Jan 21;20(1):e0312305. doi: 10.1371/journal.pone.0312305. eCollection 2025. PLoS One. 2025. PMID: 39836702 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical